ArticleThoracic cancer2026
Multi-Omics Analysis Reveals Differentially Expressed Proteins and Metabolites in Malignant Pleural Effusion.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMalignant pleural effusion (MPE) is a common manifestation in advanced malignancies. However, its differentiation from benign pleural effusions, such as parapneumonic effusion (PPE) and tuberculous pleural effusion (TPE), remains challenging. This study aimed to profile differentially expressed proteins and metabolites between MPE, PPE, and TPE.
methodsPleural effusion samples from patients with MPE, PPE, and TPE were collected and subjected to proteomic and metabolomic profiling. Differentially expressed proteins (DEPs) and differentially abundant metabolites (DAMs) were identified, followed by functional enrichment analyzes. Integrated proteome-metabolome analysis was performed to construct protein-metabolite interaction networks and reveal key pathways associated with malignant and benign pleural effusions.
resultsProteomic and metabolomic profiles differed significantly between MPE and non-MPE. Arginine-proline and glutamate metabolism were commonly enriched at both protein and metabolite levels in MPE versus PPE and TPE. At the protein level, Isocitrate Dehydrogenase 1 (IDH1) was significantly upregulated in MPE compared with both PPE and TPE. At the metabolite level, sarcosine and l-glutamine were markedly elevated, while creatine was significantly decreased in MPE. Integrated analysis further indicated that these four molecules play important roles in distinguishing MPE from PPE and TPE.
conclusionCombined proteomic and metabolomic analyzes revealed the critical involvement of IDH1 in glutamate metabolism and arginine and proline metabolic pathways during MPE metabolic reprogramming. Identified molecules, including IDH1, l-glutamine, creatine, and sarcosine, may serve as potential diagnostic biomarkers for differentiating malignant from benign pleural effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.